Article Text

Download PDFPDF
FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis
  1. Ian P Blair1,2,
  2. Kelly L Williams1,
  3. Sadaf T Warraich1,2,
  4. Jennifer C Durnall1,
  5. Annora D Thoeng1,3,
  6. Jim Manavis4,
  7. Peter C Blumbergs4,
  8. Steve Vucic5,
  9. Matthew C Kiernan6,
  10. Garth A Nicholson1,2,7
  1. 1ANZAC Research Institute, Concord Hospital, Sydney, Australia
  2. 2Sydney Medical School, University of Sydney, Sydney, Australia
  3. 3Department of Physiology, University of Sydney, Sydney, Australia
  4. 4Hanson Institute Centre for Neurological Diseases, Institute of Medical and Veterinary Science, Adelaide, Australia
  5. 5Department of Neurology, Westmead Hospital, Sydney, Australia
  6. 6Prince of Wales Medical Research Institute and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
  7. 7Molecular Medicine Laboratory, Concord Hospital, Sydney, Australia
  1. Correspondence to Dr I P Blair, Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord Hospital, Concord, NSW 2139, Australia; iblair{at}


Objective FUS gene mutations were recently identified in familial amyotrophic lateral sclerosis (ALS). The present studies sought to define the clinical, post-mortem and neurophysiological phenotypes in ALS families with FUS mutations and to determine the frequency of FUS mutations in familial and sporadic ALS.

Methods FUS was screened for mutations in familial and sporadic ALS cases. Clinical, post-mortem and neurophysiological features of large families with FUS mutations are described.

Results and conclusions FUS mutations were evident in 3.2% (4/124) of familial ALS, representing the second most common gene abnormality to be described in familial ALS after SOD1. No mutations were present in 247 sporadic ALS cases. The clinical presentation in 49 affected patients was consistent with a predominantly lower motor neuron disorder, supported by post-mortem findings. Upper motor neuron involvement varied, with Wallerian degeneration of corticospinal tracts present in one post-mortem case but absent in a second case from the same family. Features of cortical hyperexcitability demonstrated upper motor neuron involvement consistent with other forms of familial and sporadic ALS. One case presented with frontotemporal dementia (FTD) indicating that this may be a rare presenting feature in families with FUS mutation. Ubiquitin-positive cytoplasmic skein-like inclusions were present in lower motor neurons, but in contrast to sporadic ALS, no TDP-43 pathology was evident. Mutation-specific clinical features were identified. Patients with a R521C mutation were significantly more likely to develop disease at a younger age, and dropped-head syndrome was a frequent feature. Reduced disease penetrance was evident among most affected families.

  • Amyotrophic lateral sclerosis
  • mutation
  • clinical features
  • pathology
  • neurophysiology
  • genetics
  • ALS

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding This work was supported by the Peter Stearne grant for familial MND from the Motor Neurone Disease Research Institute of Australia (MNDRIA), a Clinical Fellowship to SV from the MNDRIA, the Stephen Buckley motor neuron disease research grant from Australian Rotary Health, a National Health and Medical Research Council of Australia (NHMRC) Career Development Award (511941) to IPB, and project grants (510233 and 570957) from the NHMRC of Australia.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethics approval was provided by the Sydney South West Area Health Service, Sydney, Australia.

  • Provenance and peer review Not commissioned; externally peer reviewed.